VACS Cancer Core Robert Dubrow, PhD, MD Founding Director

Slides:

Advertisements

Similar presentations

Cardiovascular Side Effects of HIV Treatment

Advertisements

Hcv infection and management in advanced liver disease

Biomarkers of Inflammation, Coagulation and Monocyte Activation Are Strongly Associated with the VACS Index among Veterans on cART Amy Justice* 1,2, Matthew.

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER CROI 2015: Hot Topics in HIV Primary Care Brian R. Wood, MD Assistant Professor of Medicine, University.

Cardiovascular Disease: Predicting Risk and Monitoring Outcomes Monica R. Shah, MD, FACC NHLBI AIDS Coordinator Conference on Retroviruses and Opportunistic.

Slide 1 of 11 From DA Wohl, MD, at New York, NY: May 03, 2012, IAS-USA. IAS–USA David Alain Wohl, MD Associate Professor of Medicine The University of.

Should We be Measuring Mortality in HIV Clinical Programs? September 13 th, 2012 Steven Johnson MD Director, University of Colorado HIV/AIDS Clinical Program;

Translational Science in Cancer Health Disparities Research Peter Ujhazy, M.D., Ph.D. Program Director Translational Research Program Division of Cancer.

Results Compliance with Breast Cancer Screening Guidelines in the HIV Clinic: A Quality Improvement Tool E. Patrozou M.D., E. Christaki M.D., L. Hicks.

ASSOCIATION OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL WITH INCIDENT CARDIOVASCULAR EVENTS IN WOMEN, BY LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND APOLIPOPROTEIN.

Veterans Aging Cohort Study (VACS)

HIV Testing in Acute Care Settings Rich Rothman, MD, PhD, FACEP CDC, DHHS, OraSure Technologies, Abbott  Historical.

This presentation is intended for educational use only, and does not in any way constitute medical consultation or advice related to any specific patient.

Figure 2: Trends in currently prescribed antiretroviral therapy % prescribed HAART increased from 74% to 83% Trends in ART use, HIV viral load, and CD4.

Slideset on: Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the.

1 Predictors of Immunological Failure Among Adult Patients Receiving ART at an urban, HIV Clinic in Uganda Dr. Muhumuza Simon (M.D, MPH) Mulago-Mbarara.

Veterans Aging Cohort Study (VACS)

Cancer Trends in North America Over the Past Decade

Harvard T.H. Chan School of Public Health

VACS Pulmonary & Critical Care Core

Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.

Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.

Hepatitis C Incidence and Prevalence in the U.S.

Figure 1. Prevalence of undocumented hepatitis C virus (HCV) infection, by age, race, and sex in 4713 emergency department patients, From: Evaluation.

VACS Physical Function & Disability Working Group

A. Stepanov, A. Kruk, N. Polovinkina, A. Vinogradova

VACS Alcohol and Behavior Change Core

HSR Core Co-Chairs: Emily Wang, MD Kathleen McGinnis, DrPH

Lesson 3: The HCV Care Continuum

VACS Polypharmacy Workgroup

Adetunji Adejumo, MD; Cynthia Lee MA; Sharon Mannheimer, MD

DOES HIV/ HEPATITIS COINFECTION AFFECT PEOPLE ACCESSING CARE FOR HIV

Janet P. Tate, MPH, ScD Co-Director

Figure 1. Study population diagram

Lesson 4: Preventing HCV Reinfection

VACS Opioids Workgroup

Non-AIDS cancers Pr. Jean-Philippe SPANO Marianne VEYRI

Maria Rodriguez-Barradas

VACS Cardiovascular Disease Core

Les Lang Gastroenterology Volume 133, Issue 1, (July 2007)

Tiffany G. Harris, PhD, MS Director of Strategic Information

Volume 13, Issue 12, Pages (December 2012)

Les Lang Gastroenterology Volume 133, Issue 1, (July 2007)

VACS Endocrine and Bone Workgroup

Hepatitis C in the HIV-infected patient

Future challenges for clinical care of an ageing population infected with HIV: a modelling study Dr Mikaela Smit, PhD, Kees Brinkman, MD, Suzanne Geerlings,

Age and Racial/Ethnic Differences in the Prevalence of Reported Symptoms in Human Immunodeficiency Virus-Infected Persons on Antiretroviral Therapy Michael.

VACS Cardiovascular Disease Core

Infections and Biologic Therapy in Rheumatoid Arthritis

Volume 13, Issue 12, Pages (December 2012)

Presenter Disclosure Information

Pneumococcal Polysaccharide (PV) Vaccine Failures among HIV-infected Veterans Compared to Non-HIV-infected controls. Maria C. Rodriguez-Barradas, MD.

Cholesterol Management in HIV-infected and Uninfected Patients: The Veterans Aging Cohort Study Leaf, DA, Goulet J, Goetz MB, Oursler KA, Gilbert C, Frieberg.

Amy C. Justice, MD, PhD For the VACS Project Team

Integrating and Prioritizing HIV and “non HIV” Care in the cART Era

Depression Treatment in HIV-infected and Uninfected Veterans: Do Rates Vary by HIV Status? Kristen Sueoka YSM IV.

The Power of Propensity Score Matching to Remove Confounding by Indication: Statins and Acute Myocardial Infarction among HIV Infected and Uninfected.

Patterns, predictors, and consequences of non-medical use prescription opioids in the Veterans Aging Cohort Study Brandon DL Marshall, PhD Manning Assistant.

Aging and HIV: Key Questions and Unifying Concepts

VACS Antiviral Workgroup

Potential mechanisms whereby statins may reduce the risk of stroke

Jeffrey P. Anderson Combination Antiretroviral Therapy and Hepatic Decompensation in HIV/HCV Coinfected Veterans JEFFREY P. ANDERSON.

VACS Mental Health WG Joseph L. Goulet, PhD, MS Director

Biostatistics Core Members Joyce Chang Kirsha Gordon Joseph Goulet

Lung Diseases in HIV-infected Veterans

VACS Scientific Meeting 2016

Volume 373, Issue 9672, Pages (April 2009)

VACS Statins Workgroup

Lesson 3: The HCV Care Continuum

Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States Ahmet Ergin, MD, PhD, MPH, Paul.

Presentation transcript:

VACS Cancer Core Robert Dubrow, PhD, MD Founding Director Lesley Park, PhD, MPH Current Co-Director Keith Sigel, MD, MPH Current Co-Director Members: Roger Bedimo, Sheldon Brown, Kristina Crothers, Cynthia Gibert, Matthew Goetz, Maria Rodriguez-Barradas, Fatma Shebl, Roxanne Wadia, Amy Justice *Lesley used VACS data for her PhD Dissertation at Yale School of Public Health completed Spring 2015 with funding from NCI (F31-CA180775)

Recent VACS Cancer Core Highlights (2015-2016) Peer Reviewed Publications Sigel K, et al. Immunologic and Infectious Risk Factors for Lung Cancer in HIV Infection. Lancet HIV 2016 (in press). Park LS, et al. Viral suppression predicts lower AIDS- and non-AIDS-related cancer incidence in a cohort of HIV-infected Veterans. (under consideration Annals of Internal Medicine). Park LS, et al. Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era: 1997-2012. AIDS 2016. Park LS, et al. Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis. AIDS 2016. Althoff KN, et al. Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clin Infect Dis. 2015. Lo Re V, et al. Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients. Open Forum Infect Dis. 2015. Consortium Collaborations Shiels M, et al. HIV Infection, immune suppression and age at diagnosis of non-AIDS-defining cancers. Clin Infect Dis 2016 (in press). (NA-ACCORD) Silverberg M, et al. Cumulative incidence of cancer among HIV-infected patients in North America. Ann Intern Med 2015. (NA-ACCORD) Conference Presentations CROI 2015, 2016, ICMAOI 2015, IWHOD 2015 New Grants National Cancer Institute R01 “Optimizing Lung Cancer Treatment in HIV” (Sigel) – Fundable Score Yale Cancer Center Pilot Grant “COPD / Lung Cancer in HIV” (Akgun)

VACS Cancer Core Highlights